Compare Enveric Biosciences Inc (ENVB) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Enveric Biosciences Inc trades at $1.39 (market cap $5.32M), while Invesco S&P 500 Low Volatility ETF trades at $76.58. The key difference: Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | SPLV | |
|---|---|---|
Market Cap | $5.32M | — |
Sector | Health | — |
52-Week High | $17.40 | $77.45 |
52-Week Low | $1.28 | $70.30 |
Enterprise Value | $408.82K | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
The Invesco S&P 500 Low Volatility ETF (SPLV) trades at $76.58, up 0.88% on the day, with a bullish technical signal from moving averages. The ETF provides exposure to 100 large-cap US stocks selected for their low historical volatility, offering a defensive tilt. Recent news highlights its role as a portfolio diversifier amid tech sell-offs and geopolitical tensions, with a scheduled dividend of $0.14 per share in June 2026.
SPLV offers a defensive equity strategy for investors seeking lower volatility than the broader market. The outlook is supported by its historical resilience during downturns, but its performance is inherently tied to market conditions that favor low-volatility factors. Key risks include underperformance during strong bull markets and the quarterly reconstitution of its underlying index.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
